ETS2 and acute myeloid leukemia: Cohort studies have identified the overexpression of ERG and ETS2 as a biomarker correlated with an adverse clinical outcome in AML patients, with ETS2 hypothesized to induce apoptosis (in the presence of p53) and ERG crucial for leukemic maintenance (96–100).